118 Meeting through WebEx Video-conference of the DTAB-sub Committee on 05.04.2024 at 11.00 a.m. to 6:00 p.m. to Evaluation of 16 FDCs which were earlier considered as irrational in the Expert Committ

.

‘

F.NO. 4-01/2013-DC (Misc. 13 PSC -Part-lll) Government of India Directorate General of Health Services Central Drugs Standard Control Organization (FDC Division)

==> picture [129 x 25] intentionally omitted <==

----- Start of picture text -----<br> ele. No. : 011-23236965<br>Fax No. : 011-23236973<br>----- End of picture text -----<br>

FDA Bhawan, Kotla Road New Delhi-110002 Dated: 5 6

NOTICE

Subject:-Meeting through WebEx (Video-conference) of the DTAB-sub Committee on 05.04.2024 at 11.00 a.m. to 6:00 p.m. to Evaluation of 16 FDCs which were earlier considered as irrational in the Expert Committee report of the Prof. Kokate Committee -regarding.

This is in reference to the Notice vide F.No. 04-01/2013-DC(Misc. 13-PSC Part-II!) dated 31.03.2023 from this office on the subject cited above. Accordingly, some of the applicants/stakeholders have submitted the information in prescribed format as per AnnexureA which needs to be deliberated with the DTAB-sub Committee.

In order to evaluate these proposals, a meeting has been scheduled on 05.04.2024 at 11:00 am through WebEx Video conference. During the meeting, applicants/stakeholders will be asked to make a presentation before the committee for further recommendation on such FDCs. It is requested to kindly make it convenient to attend the meeting on the said date through WebEx (Video-conference) before the DTAB-sub Committee. In the event that the Stakeholders does not attend the hearing, the Committee reserves the right to make its decision on the basis of information available before it. The weblink will be shared on the date of the meeting. Applicants/stakeholders are also requested to forward details of presenter, e- mail |D, contact number along with PPT presentation at fdc@cdsco.nic.in by 02.04.2024.

This is for information of all concerned.

==> picture [68 x 11] intentionally omitted <==

----- Start of picture text -----<br> Yours faithfully<br>----- End of picture text -----<br>

(Deepak Kumar) Assistant Drugs Controller (Indi

• Copy to: 1.Dr. Nilima Kshirsagar, Former Chair in Clinical Pharmacology, ICMR, Mumbai, chairperson, sub-committe of DTAB.

• 2.To all the experts committee members. 3.Indian Drug/Pharmaceuticals Association (IDMA/FOPE/CIPI/IPA/OPPI, etc.,) with the

• request to communicate it to your members and publicize it widely so that all concerned , can avail this opportunity. 4. Website of CDSCO for information and necessary by concerned stakeholders.